A Novel Nomogram Combining Mucus Barrier Index for Predicting Treatment Failures in Ulcerative Colitis

References

• Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: east meets west. J Gastroenterol Hepatol. 2019;35:380–389. doi:10.1111/jgh.14872
   PubMed Web of Science ®Google Scholar
• Eisenstein M. Ulcerative colitis: towards remission. Nature. 2018;563(7730):S33. doi:10.1038/d41586-018-07276-2
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727. doi:10.1038/nrgastro.2015.150
   PubMed Web of Science ®Google Scholar
• Burisch J, Lophaven S, Munkholm P, Langholz E. Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962–1987 and followed until 2017 in a Danish population-based inception cohort. Aliment Pharmacol Ther. 2022;55(3):339–349. doi:10.1111/apt.16677
   PubMed Web of Science ®Google Scholar
• Mattioli G, Barabino A, Aloi M, et al. Paediatric ulcerative colitis surgery: Italian survey. J Crohns Colitis. 2015;9(7):558–564. doi:10.1093/ecco-jcc/jjv065
   PubMed Web of Science ®Google Scholar
• Cucchiara S, Stronati L. Ulcerative colitis: paediatric ulcerative colitis--can we predict proctocolectomy? Nat Rev Gastroenterol Hepatol. 2012;9(9):494–495. doi:10.1038/nrgastro.2012.153
   PubMed Web of Science ®Google Scholar
• Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–355.e352. doi:10.1053/j.gastro.2015.04.016
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Danese S, Argollo M, et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with crohn’s disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(5):838–846.e832. doi:10.1016/j.cgh.2018.06.026
   PubMed Web of Science ®Google Scholar
• Protic M, Seibold F, Schoepfer A, et al. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J Crohns Colitis. 2014;8(11):1427–1437. doi:10.1016/j.crohns.2014.05.004
   PubMed Web of Science ®Google Scholar
• Stellingwerf ME, Sahami S, Winter DC, et al. Prospective cohort study of appendicectomy for treatment of therapy-refractory ulcerative colitis. Br J Surg. 2019;106(12):1697–1704. doi:10.1002/bjs.11259
   PubMed Web of Science ®Google Scholar
• Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol. 1993;88(6):852–855.
   PubMed Web of Science ®Google Scholar
• Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Schneeweiss S, Kim SC. Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn’s disease. Gut. 2022;71(9):1781–1789. doi:10.1136/gutjnl-2022-327002
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao J, Wang H, Zheng C, Chang B, Sang L. Methotrexate showed efficacy both in Crohn’s disease and ulcerative colitis, predictors of surgery were identified in patients initially treated with methotrexate monotherapy. Front Pharmacol. 2022;13:996065. doi:10.3389/fphar.2022.996065
   PubMed Web of Science ®Google Scholar
• Dalal RS, Osterman MT, Buchner AM, Praestgaard A, Lewis JD, Lichtenstein GR. A user-friendly prediction tool to identify colectomy risk in patients with ulcerative colitis. Inflamm Bowel Dis. 2019;25(9):1550–1558. doi:10.1093/ibd/izz014
   PubMed Web of Science ®Google Scholar
• Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58(12):1612–1619. doi:10.1136/gut.2009.178665
   PubMed Web of Science ®Google Scholar
• Johansson ME, Gustafsson JK, Holmen-Larsson J, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. 2014;63(2):281–291. doi:10.1136/gutjnl-2012-303207
   PubMed Web of Science ®Google Scholar
• EEL N, Martinez-Abad B, Arike L, et al. An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function. Science. 2021;372:6539.
   Web of Science ®Google Scholar
• van der Post S, Jabbar KS, Birchenough G, et al. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut. 2019;68(12):2142–2151. doi:10.1136/gutjnl-2018-317571
   PubMed Web of Science ®Google Scholar
• Takishima K, Maeda Y, Ogata N, et al. Beyond complete endoscopic healing: goblet appearance using an endocytoscope to predict future sustained clinical remission in ulcerative colitis. Dig Endosc. 2022;34(5):1030–1039. doi:10.1111/den.14202
   PubMed Web of Science ®Google Scholar
• Ozaki R, Kobayashi T, Okabayashi S, et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J Crohns Colitis. 2018;12(11):1288–1294. doi:10.1093/ecco-jcc/jjy092
   PubMed Web of Science ®Google Scholar
• Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131(1):117–129. doi:10.1053/j.gastro.2006.04.020
   PubMed Web of Science ®Google Scholar
• Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965–990. doi:10.1016/j.crohns.2012.09.003
   PubMed Web of Science ®Google Scholar
• Lobatón T, Bessissow T, De Hertogh G, et al. The Modified Mayo Endoscopic Score (MMES): a new index for the assessment of extension and severity of endoscopic activity in ulcerative colitis patients. J Crohns Colitis. 2015;9(10):846–852. doi:10.1093/ecco-jcc/jjv111
   PubMed Web of Science ®Google Scholar
• Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120(1):13–20. doi:10.1053/gast.2001.20912
   PubMed Web of Science ®Google Scholar
• Li Y, Nuij VJ, Baars JE, et al. Increased suppressor of cytokine signaling-3 expression predicts mucosal relapse in ulcerative colitis. Inflamm Bowel Dis. 2013;19(1):132–140. doi:10.1002/ibd.22992
   PubMed Web of Science ®Google Scholar
• Mañosa M, García V, Castro L, et al. Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. J Crohns Colitis. 2011;5(5):397–401. doi:10.1016/j.crohns.2011.03.012
   PubMed Web of Science ®Google Scholar
• Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909–1915. doi:10.1016/S0140-6736(12)61084-8
   PubMed Web of Science ®Google Scholar
• Beswick L, Rosella O, Rosella G, et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study. J Crohns Colitis. 2018;12(3):289–297. doi:10.1093/ecco-jcc/jjx146
   PubMed Web of Science ®Google Scholar
• Obraztsov IV, Shirokikh KE, Obraztsova OI, Shapina MV, Wang MH, Khalif IL. Multiple cytokine profiling: a new model to predict response to tumor necrosis factor antagonists in ulcerative colitis patients. Inflamm Bowel Dis. 2019;25(3):524–531. doi:10.1093/ibd/izy358
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255–260. doi:10.1053/gast.2001.26279
   PubMed Web of Science ®Google Scholar
• Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145(1):158–165.e152. doi:10.1053/j.gastro.2013.04.007
   PubMed Web of Science ®Google Scholar
• Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepatol. 2011;26(7):1114–1122. doi:10.1111/j.1440-1746.2011.06688.x
   PubMed Web of Science ®Google Scholar
• Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59(9):1207–1212. doi:10.1136/gut.2010.211755
   PubMed Web of Science ®Google Scholar
• Schechter A, Griffiths C, Gana JC, et al. Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric ulcerative colitis. Gut. 2015;64(4):580–588. doi:10.1136/gutjnl-2014-306999
   PubMed Web of Science ®Google Scholar
• Hamanaka S, Nakagawa T, Hiwasa T, et al. Investigation of novel biomarkers for predicting the clinical course in patients with ulcerative colitis. J Gastroenterol Hepatol. 2018;33(12):1975–1983. doi:10.1111/jgh.14297
   PubMed Web of Science ®Google Scholar
• Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(3):531–538. doi:10.1016/j.cgh.2014.07.055
   PubMed Web of Science ®Google Scholar
• McAuley JL, Linden SK, Png CW, et al. MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J Clin Invest. 2007;117(8):2313–2324. doi:10.1172/JCI26705
   PubMed Web of Science ®Google Scholar
• McDermott KM, Crocker PR, Harris A, et al. Overexpression of MUC1 reconfigures the binding properties of tumor cells. Int J Cancer. 2001;94(6):783–791. doi:10.1002/ijc.1554
   PubMed Web of Science ®Google Scholar
• Breugelmans T, Van Spaendonk H, De Man JG, et al. In-depth study of transmembrane mucins in association with intestinal barrier dysfunction during the course of T cell transfer and DSS-induced colitis. J Crohns Colitis. 2020;14(7):974–994. doi:10.1093/ecco-jcc/jjaa015
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Loening-Baucke V, Theissig F, et al. Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut. 2007;56(3):343–350. doi:10.1136/gut.2006.098160
   PubMed Web of Science ®Google Scholar
• Singh V, Johnson K, Yin J, et al. Chronic inflammation in ulcerative colitis causes long-term changes in goblet cell function. Cell Mol Gastroenterol Hepatol. 2022;13(1):219–232. doi:10.1016/j.jcmgh.2021.08.010
   PubMed Web of Science ®Google Scholar
• Larsson JM, Karlsson H, Crespo JG, et al. Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm Bowel Dis. 2011;17(11):2299–2307. doi:10.1002/ibd.21625
   PubMed Web of Science ®Google Scholar
• Bessissow T, Kron CM, Marcus V, et al. Impact of endoscopic and histologic activity on disease relapse in ulcerative colitis. Am J Gastroenterol. 2022;117(10):1632–1638. doi:10.14309/ajg.0000000000001912
   PubMed Web of Science ®Google Scholar
• Ohara J, Nemoto T, Maeda Y, Ogata N, Kudo SE, Yamochi T. Deep learning-based automated quantification of goblet cell mucus using histological images as a predictor of clinical relapse of ulcerative colitis with endoscopic remission. J Gastroenterol. 2022;57(12):962–970. doi:10.1007/s00535-022-01924-1
   PubMed Web of Science ®Google Scholar
• Tursi A, Elisei W, Picchio M, et al. Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. Eur J Intern Med. 2014;25(8):757–761. doi:10.1016/j.ejim.2014.07.007
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY). Gastroenterology. 2021;161(4):1156–1167.e1153. doi:10.1053/j.gastro.2021.06.015
   PubMed Web of Science ®Google Scholar